A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorCentessa Pharmaceuticals (UK) Limited

About this trial

Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.

Eligibility criteria

Qualifiers

Healthy males or females as determined by assessments at the Screening Visit.

Disqualifiers

Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.

History of seizure disorder, any other condition that increases the risk of seizure

Has a clinically significant sleep disorder, including insomnia or sleep apnea.

Trial design

Treatments tested in this trial

  • ORX142 Tablets
  • Placebo Tablets

Treatment groups

208 Participants
are divided into 5 treatment groups